Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
Luigi Gargiulo(Humanitas University), Antonio Costanzo(Humanitas University), Diego Orsini(San Gallicano Hospital), Martina Maurelli(University of Verona), Luca Bianchi(University of Rome Tor Vergata), Angelo Valerio Marzano(University of Milan), Francesco Loconsole(University of Bari Aldo Moro), Edoardo Mortato(University of Bari Aldo Moro), Annunziata Dattola(University of Rome Tor Vergata), Matteo Megna(University of Padua), Annamaria Offidani(Marche Polytechnic University), Francesco Cusano(Azienda Ospedaliera G.Rummo), Piergiorgio Malagoli(IRCCS Policlinico San Donato), Antonio Giovanni Richetta(Sapienza University of Rome), Anna Campanati(Marche Polytechnic University), Pina Brianti(Vita-Salute San Raffaele University), Dario Buononato(University of Campania "Luigi Vanvitelli"), Paolo Dapavo(University of Turin), Marina Venturini(University of Brescia), Santo Raffaele Mercuri(Vita-Salute San Raffaele University), Vincenzo Maione(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Anna Balato(University of Naples Federico II), Luca Potestio(University of Naples Federico II), Martina Burlando(Ospedale Policlinico San Martino), Luciano Ibba(Humanitas University), Pietro Quaglino(Department of Medical Sciences), Giacomo Caldarola(Università Cattolica del Sacro Cuore), Andrea Carugno(University of Insubria), Paolo Sena(Ospedale Papa Giovanni XXIII), Alessandro Giunta(University of Rome Tor Vergata), Clara De Simone(IRCCS San Camillo Hospital), Alessandra Narcisi(IRCCS Humanitas Research Hospital), Francesca Maria Gaiani(IRCCS Policlinico San Donato), Elena Campione(University of Rome Tor Vergata), Paolo Gisondi(University of Verona), Aurora Parodi(Ospedale Policlinico San Martino), Francesca Romano(University of Campania "Luigi Vanvitelli"), Giovanni Pellacani(Sapienza University of Rome), Carlo Giovanni Carrera(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Antonio Cristaudo(San Gallicano Hospital)
Cited by 55
Related Papers
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
|JAMA Dermatology|2015|452
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017
|European Journal of Cancer|2017|449
The Impact of In Vivo Reflectance Confocal Microscopy for the Diagnostic Accuracy of Melanoma and Equivocal Melanocytic Lesions
|Journal of Investigative Dermatology|2007|444